ArticleEndocrine, metabolic & immune disorders drug targets2026
Association of Fibrinogen-Like Protein 1 with Metabolic Disorders and Pregnancy Outcomes: A Case-Control Study
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the relationship between fibrinogen-like protein 1 (FGL1) and adverse pregnancy outcomes (APOs) as well as metabolic disorders during pregnancy.
methodsThe pregnant women from 24 to 28 weeks of gestation were divided into different groups according to the number of metabolic abnormalities in a 2:1:1 ratio. A total of 120 cases were in the normal metabolic group, 120 cases were in the one metabolic disorder group, and 60 cases were in the two or more metabolic disorder groups. Blood collection and other sample collections were performed at 24-28 weeks of gestation.
resultsSerum FGL1 levels increased gradually across the normal metabolism group, one metabolic disorder group, and the two or more metabolic disorders group (H=9.410, P=0.009). Serum FGL1 level was extensively higher in the gestational diabetes mellitus (GDM) group compared to the normal glucose tolerance group (P<0.001). Compared with 190 women without APOs, serum FGL1 was higher in 59 women who developed adverse outcomes (P<0.05). Receiver operating characteristic (ROC) curve analysis showed that the combination of FGL1 with traditional indicators had higher predictive performance for APOs, with the area under the AUC of 0.718, than that of traditional indicators alone (AUC=0.700). DISCUSSION: High serum FGL1 may be a potential biomarker to monitor the severity of metabolic abnormality to enhance the predictive capability of traditional biomarkers for APOs.
conclusionSerum FGL1 in mid-pregnancy was closely related to metabolic disorders, GDM, and APOs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.